Log in

NASDAQ:RAREUltragenyx Pharmaceutical Stock Price, Forecast & News

+0.28 (+0.33 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $84.84
50-Day Range
MA: $81.39
52-Week Range
Now: $84.84
Volume289,732 shs
Average Volume370,283 shs
Market Capitalization$5.14 billion
P/E RatioN/A
Dividend YieldN/A
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
Read More
Ultragenyx Pharmaceutical logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:RARE



Sales & Book Value

Annual Sales$103.71 million
Book Value$11.48 per share


Net Income$-402,730,000.00
Net Margins-188.51%


Market Cap$5.14 billion
Next Earnings Date11/3/2020 (Estimated)
+0.28 (+0.33 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RARE News and Ratings via Email

Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions

How has Ultragenyx Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

Ultragenyx Pharmaceutical's stock was trading at $45.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RARE shares have increased by 87.1% and is now trading at $84.84.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Ultragenyx Pharmaceutical?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ultragenyx Pharmaceutical

When is Ultragenyx Pharmaceutical's next earnings date?

Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Ultragenyx Pharmaceutical

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) announced its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported ($1.91) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.68) by $0.23. The biopharmaceutical company had revenue of $36.31 million for the quarter, compared to analyst estimates of $36.74 million. Ultragenyx Pharmaceutical had a negative net margin of 188.51% and a negative return on equity of 56.12%. Ultragenyx Pharmaceutical's revenue was up 99.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.82) earnings per share.
View Ultragenyx Pharmaceutical's earnings history

What price target have analysts set for RARE?

16 equities research analysts have issued twelve-month target prices for Ultragenyx Pharmaceutical's stock. Their forecasts range from $64.00 to $99.00. On average, they expect Ultragenyx Pharmaceutical's stock price to reach $82.50 in the next year. This suggests that the stock has a possible downside of 2.8%.
View analysts' price targets for Ultragenyx Pharmaceutical

What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock?

Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:
  • 1. According to Zacks Investment Research, "Ultragenyx witnessed growth in the demand for Crysvita for both children and adults with X-linked hypophosphatemia in the United States. The drug's performance has been impressive so far. The company is also expanding the label of the drug and filed an sBLA for the same for the treatment of tumor-induced osteomalacia. The company’s NDA for a potential approval of its third therapy, UX007, in fatty acid oxidation disorders is under review with the FDA. Ultragenyx continues to advance two gene-therapy clinical programs — DTX401 for glycogen storage disease type Ia and DTX301 for ornithine transcarbamylase deficiency. However, being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses and the need for additional capital." (4/16/2020)
  • 2. Cowen Inc analysts commented, "Matinas reported 2Q19 with net loss of ($3.6M) and ended the period with $36.8M in cash on the balance sheet. The company should have runway through 2020 and through multiple catalysts; Omega-3 (OM3) asset MAT9001 and antifungal MAT2203 (amphotericin)." (8/15/2019)

Has Ultragenyx Pharmaceutical been receiving favorable news coverage?

Media headlines about RARE stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ultragenyx Pharmaceutical earned a media sentiment score of 1.3 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about Ultragenyx Pharmaceutical

Who are some of Ultragenyx Pharmaceutical's key competitors?

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Gilead Sciences (GILD), Exelixis (EXEL), TG Therapeutics (TGTX), Portola Pharmaceuticals (PTLA), Sangamo Therapeutics (SGMO), AbbVie (ABBV), Crispr Therapeutics (CRSP), GALAPAGOS NV/S (GLPG), GW Pharmaceuticals PLC- (GWPH) and Intercept Pharmaceuticals (ICPT).

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the following people:
  • Emil D. Kakkis, President, Chief Executive Officer & Director
  • Wladimir Hogenhuis, Chief Operating Officer
  • Shalini Sharp, Chief Financial Officer & Executive Vice President
  • Dennis Karl Huang, Chief Technical Operations Officer & Senior VP
  • Eric Crombez, Chief Medical Officer

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional investors include First Trust Advisors LP (1.96%), New York State Common Retirement Fund (0.21%), Swiss National Bank (0.20%), Rhenman & Partners Asset Management AB (0.10%), Mackay Shields LLC (0.07%) and Russell Investments Group Ltd. (0.06%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski.
View institutional ownership trends for Ultragenyx Pharmaceutical

Which major investors are selling Ultragenyx Pharmaceutical stock?

RARE stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Russell Investments Group Ltd., SG Americas Securities LLC, Rhenman & Partners Asset Management AB, Virtus ETF Advisers LLC, Mutual of America Capital Management LLC, RMB Capital Management LLC, and Mitsubishi UFJ Kokusai Asset Management Co. Ltd.. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, and Theodore Alan Huizenga.
View insider buying and selling activity for Ultragenyx Pharmaceutical

Which major investors are buying Ultragenyx Pharmaceutical stock?

RARE stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, New York State Common Retirement Fund, Swiss National Bank, Trexquant Investment LP, Rafferty Asset Management LLC, ProShare Advisors LLC, Principal Financial Group Inc., and Strs Ohio.
View insider buying and selling activity for Ultragenyx Pharmaceutical

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $84.84.

How big of a company is Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical has a market capitalization of $5.14 billion and generates $103.71 million in revenue each year. The biopharmaceutical company earns $-402,730,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis.

What is Ultragenyx Pharmaceutical's official website?

The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.